borderline significanceP = 0.073
There was a trend toward higher HHV-6B DNA concentration in ME/CFS-MM participants than HC, with borderline significance at months 3 ( P = 0.073) and 5 ( P = 0.080).
There was a trend toward higher HHV-6B DNA concentration in ME/CFS-MM participants than HC, with borderline significance at months 3 ( P = 0.073) and 5 ( P = 0.080).
In the pattern 1 ME/CFS_SA group (fluctuating levels of HHV DNA in saliva) there were strong and highly significant associations between HHV-6B DNA concentration and six symptom domain scores (sleep dysfunction, pain, neurocognition, autonomic, neuroendocrine and immune, r = 0.47, 0.52, 0.65, 0.50, 0.46, and 0.41, respectively, all P ≤ 0.01).